Work

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

Year: 2004

Type: article

Study design: Clinical Trial

Source: British Journal of Haematology

DOI: 10.1111/j.1365-2141.2004.05188.x

Authors: S. Jagannath, B. Barlogie, J. Berenson, D. Siegel, D. Irwin, P. G. Richardson, R. Niesvizky, R. Alexanian, S. A. Limentani, M. Alsina, J. Adams, M. Kauffman, D.‐L. Esseltine, D. P. Schenkein, K. C. Anderson

Institutions: Saint Vincent's Catholic Medical Center, University of Arkansas at Little Rock, Institute for Myeloma & Bone Cancer Research, Hackensack University Medical Center, Alta Bates Summit Medical Center, Dana-Farber Cancer Institute, NewYork–Presbyterian Hospital, Cornell University, The University of Texas MD Anderson Cancer Center, Hematology Oncology Associates, Moffitt Cancer Center, Infinity Pharmaceuticals (United States), Takeda Oncology (United States)

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Takeda Oncology

OpenAlex ID: W2107154392

FWCI: 39.07

Cites: 16

Cited by: 740

Related to: 10